[18F]PI-2620 yielded a high sensitivity for detection of patients with PSP in our recent multi-center evaluation and could potentially serve as a screening criterion in anti-tau PSP trials [6]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.